Increased simplicity, broader financial risk sharing, and an enhanced focus on patient care were among the recommendations developed by diverse stakeholders at a recent AMCP Partnership Forum focused on how to better manage the high costs of specialty medications.
Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management programs are designed to improve the health of persons with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively, thus slowing the progression of those diseases.
Over the past several years, the introduction, utilization and cost share of specialty pharmacy products has been increasing at a rate substantially greater than that of other pharmaceuticals. This paper examines the characteristics of specialty pharmaceuticals; the growth of new expertise to handle and manage these pharmaceuticals; and the needs these products create for patients, health plans and practitioners.
AMCP webinar that discussed pipeline agents for Duchenne Muscular Dystrophy.
![AMCP Caragon](https://amcp.org/sites/default/files/styles/card_fullsize/public/images/Caragon%20200x200_1%20%281%29.png.webp?itok=u3B0V_o4)
AMCP webinar that discussed pipeline agents for Duchenne Muscular Dystrophy.